Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 44

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 44
---
 update any of the forward-looking statements after the date this Prospectus is filed to confirm these statements to actual results, unless required by law.

You should not place undue reliance on forward looking statements. The cautionary statements set forth in this Prospectus identify important factors which you should consider in evaluating our forward-looking statements. These risks and uncertainties may include, without limitation, risks related to general economic and business conditions; our ability to continue as a going concern; our ability to obtain financing necessary to operate our business; our ability to consummate the Share Exchange Agreement with LipoVation (as described below); our ability to recruit and retain qualified personnel; our ability to manage any future growth; our ability to research and successfully develop our planned products; our ability to successfully complete potential acquisitions and collaborative arrangements; and other factors including those set forth below under the caption “ Risk Factors.”

This Prospectus also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other industry data. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified the statistical and other industry data generated by independent parties and contained in this Prospectus. In addition, projections, assumptions, and estimates of our future performance and the future performance of the industries in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors.

<div align='center'>25

USE OF PROCEEDS</div>

We estimate that the net proceeds from the sale of the Units by the Company in the Primary Offering will be approximately $4.4 million (assuming the sale of all securities offered hereby, at the fixed public offering price of $3.20 per Unit, assuming no exercise of the IPO Warrants issued in connection with this offering), after deducting the estimated offering expenses payable by us.

We intend to use the net proceeds of approximately $4.4 million we receive from the sale of the Units in this Primary Offering as follows:

| (i) | up                                                                                              
 to 80% from the net proceeds of this offering or $3.52 million will be used for the development 
 of our product candidates and conducting clinical trials;                                       |

| (ii) | up                                                                                                
 to $880,000 from the net proceeds of this offering or 20% to explore and develop additional       
 new indications and associated IP estate beyond our current pipeline. Any remaining funds         
 will be reserved for operational expenses, including personnel costs and maintaining intellectual